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Coronary atherosclerosis is a leading cause of cardiovascular
morbidity and mortality worldwide. Plaque complications
occur most commonly from plaque rupture, and also from
plaque erosion and calcified nodule formation. Over the past
years, advanced structural, metabolic and molecular imaging
technologies have emerged and offer new windows into ath-
erosclerosis pathophysiology [1–4]. Molecular imaging com-
plements traditional structural plaque imaging through the use
of targeted probes that identify specific molecules and/or
biological processes in vivo [5]. Preclinical atherosclerosis
molecular imaging has successfully identified nearly all
established high-risk plaque characteristics including inflam-
mation, thrombosis, neo-vessel formation, apoptosis, and
haemorrhage. However, clinical translation of molecular im-
aging has been slow compared with the rapid growth within
the field.
Currently, clinical atherosclerosis molecular imaging is
dominated by non-invasive PET metabolism/inflammation
plaque imaging with fluorine 18 (18F)-fluorodeoxyglucose
(FDG). For the past two decades, 18F FDG has been the only
fluorine-18 radioligand approved by the US Food and Drug
Administration (FDA) for PET imaging. Coronary FDG PET
is challenging, in part owing to the small size of coronary
vessels and cardiac motion artefacts, but also because of the
intense FDG uptake of the adjacent highly metabolic myocar-
dium that obscures the coronary FDG signal. However, with
dietary myocardial suppression protocols, detection of FDG
PET signal in the left main and proximal coronary artery beds
is sometimes achievable. Recently, non-invasive coronary
FDG PET activity has been investigated in the stented culprit
lesions of 20 subjects with acute coronary syndromes (ACS)
versus seven non-ACS subjects within 1 week of stent place-
ment [6]. Using a predetermined FDG target to background
ratio of 2.0 or greater to identify FDG-positive lesions, the
ACS patients correlated positively with elevated stent FDG
signal. However, coronary FDG signal was interpretable in
only 50 % of ACS patients, implying the need for further
improvements in coronary FDG PET.
Apart from 18F FDG coronary imaging, clinically avail-
able approaches such as sodium 18F-fluoride (NaF) for PET
are emerging. Coronary calcification is a hallmark of ad-
vanced atheroma that can be detected with non-invasive NaF
PET, which has been used for the past 3 decades to detect
cancer bone metastases. As opposed to FDG, background
myocardial uptake of NaF is negligible, and therefore NaF
can determine coronary osteogenic activity. In a study by
Dweck et al. from the University of Edinburgh [7], NaF
PET molecular imaging identified sites of active coronary
calcification non-invasively by PET and may be a new thera-
peutic target. The NaF signal was elevated in proportion to
coronary CT calcium scores in 119 subjects, except in those
with the highest calcium scores that may represent end-stage
calcified plaques. From the same research group, Joshi et al.
[8] recently (Lancet November 2013) studied coronary plaque
imaging using two different radioactive tracers: 18F-NaF and
18F-FDG. The Scottish study included 40 patients with acute
myocardial infarction (AMI) and 40 patients with stable angi-
na. All patients underwent PET-CT, invasive coronary angi-
ography, CT coronary angiography, and CT calcium scoring.
Among the 40 patients with AMI, 18F-NaF PET uptake
was 34 % higher in the culprit ruptured plaque compared with
non-culprit plaques. Nearly all patients (93 %) had increased
18F-NaF uptake in the culprit plaque. With 18F-FDG, how-
ever, no differences in uptake between culprit and non-culprit
plaques were observed. Among the 40 patients with stable
angina, 45 % had plaques with increased 18F-NaF uptake.
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These plaques were mostly non-obstructive at coronary angiog-
raphy and contained more high-risk features on intravascular
ultrasound compared with plaques without tracer uptake. Con-
sequently, 18F-NaF PET may become an effective tool for
predicting anAMI, whichwould have a great impact for patients
with coronary atherosclerosis. Early detection of the atheroscle-
rotic ‘danger zones’ could include immediate instalment of
drugs such as statins or aspirin, drastic changes in lifestyle and
even inserting stents into the affected coronary artery.
The use of 18F-NaF PET-CT offers the first non-invasive
imaging method to identify and localise ruptured and high-
risk coronary plaques. A next step is to show that increased
18F-NaF predicts future adverse clinical events. Further stud-
ies are therefore needed to evaluate whether the detection of
risky plaques before rather than after an AMI has the potential
to save lives. To summarise, the addition of newer molecular
imaging tools such as NaF PET-CTwill continue to strengthen
our understanding of the in vivo biology of high-risk plaques
[9, 10]. They are increasingly being translated into clinical
use, and in combination with structural imaging they provide
more comprehensive information to build risk-prediction
tools. Ongoing efforts to improve non-invasive coronary im-
aging strategies must be pursued. Overall, with continued
advances in molecular and structural atherosclerosis imaging,
high-risk coronary atherosclerotic plaques will be brightened
as never before. The recent study in the Lancet at least sug-
gests that molecular imaging using PET-CT scanning may
provide an answer in identifying ‘ticking time bomb’ patients
at risk of an AMI.
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